Lily Lam

Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA.

Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada.

Covington Capital Corp (Covington Capital) is a Toronto-based venture capital investment firm founded 1994. The firm is headquartered in Toranto, CA.

BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada.

Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada.

Insception Biosciences, Inc. engages in the research and development of stem cell-based treatments. It also provides cord blood banking services. The company was founded by Robert Casper in 1996 and is headquartered in Mississauga, Canada.

BTE Technologies, Inc. provides solutions for testing and rehabilitation. The firm's workforce Solutions provides employers with superior processes and technology to enable employers to optimize productivity, through lower absenteeism turnover, improved safety, reduced injuries and claims costs and measurably increased performance. . The company was founded in 2004 and is headquartered in Hanover, MD.

Bedlam Games, Inc. provided online gaming services. It offered shooting, puzzle, flying, adventure, simulation, shock wave, arcade and racing games. The company was founded in 2006 and headquartered in Toronto, Canada.